{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:17:58Z","timestamp":1791865078482,"version":"4.3.4"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Broth microdilution antimicrobial susceptibility testing was performed for ceftazidime-avibactam and comparator agents against 7,062 clinical isolates of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa<\/jats:named-content>\n            collected from 2012 to 2014 in four geographic regions (Europe, Asia\/South Pacific, Latin America, Middle East\/Africa) as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program. The majority of isolates were susceptible to ceftazidime-avibactam, with the proportions susceptible differing marginally across the four regions (MIC\n            <jats:sub>90<\/jats:sub>\n            , 8 to 16 \u03bcg\/ml; 88.7 to 93.2% susceptible), in contrast to lower susceptibilities to the following comparator \u03b2-lactam agents: ceftazidime (MIC\n            <jats:sub>90<\/jats:sub>\n            , 32 to 64 \u03bcg\/ml; 71.5 to 80.8% susceptible), meropenem (MIC\n            <jats:sub>90<\/jats:sub>\n            , &gt;8 \u03bcg\/ml; 64.9 to 77.4% susceptible), and piperacillin-tazobactam (MIC\n            <jats:sub>90<\/jats:sub>\n            , &gt;128 \u03bcg\/ml; 62.3 to 71.3% susceptible). Compared to the overall population, susceptibility to ceftazidime-avibactam of isolates that were nonsusceptible to ceftazidime (\n            <jats:italic>n<\/jats:italic>\n            = 1,627) was reduced to between 56.8% (Middle East\/Africa; MIC\n            <jats:sub>90<\/jats:sub>\n            , 64 \u03bcg\/ml) and 68.9% (Asia\/South Pacific; MIC\n            <jats:sub>90<\/jats:sub>\n            , 128 \u03bcg\/ml), but these percentages were higher than susceptibilities to other \u03b2-lactam agents (0 to 44% susceptible, depending on region and agent; meropenem MIC\n            <jats:sub>90<\/jats:sub>\n            , &gt;8 \u03bcg\/ml; 26.5 to 43.9% susceptible). For this subset of isolates, susceptibilities to amikacin (MIC\n            <jats:sub>90<\/jats:sub>\n            , &gt;32 \u03bcg\/ml; 53.2 to 80.0% susceptible) and colistin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 \u03bcg\/ml; 98.5 to 99.5% susceptible) were comparable to or higher than that of ceftazidime-avibactam. A similar observation was made with isolates that were nonsusceptible to meropenem (\n            <jats:italic>n<\/jats:italic>\n            = 1,926), with susceptibility to ceftazidime-avibactam between 67.8% (Middle East\/Africa; MIC\n            <jats:sub>90<\/jats:sub>\n            , 64 \u03bcg\/ml) and 74.2% (Europe; MIC\n            <jats:sub>90<\/jats:sub>\n            , 32 \u03bcg\/ml) but again with reduced susceptibility to comparators except for amikacin (MIC\n            <jats:sub>90<\/jats:sub>\n            , &gt;32 \u03bcg\/ml; 56.8 to 78.7% susceptible) and colistin (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 \u03bcg\/ml; 98.9 to 99.3% susceptible). Of the 8% of isolates not susceptible to ceftazidime-avibactam, the nonsusceptibility of half could be explained by their possession of genes encoding metallo-\u03b2-lactamases. The data reported here are consistent with results from other country-specific and regional surveillance studies and show that ceftazidime-avibactam demonstrates\n            <jats:italic>in vitro<\/jats:italic>\n            activity against globally collected clinical isolates of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa<\/jats:named-content>\n            , including isolates that are resistant to ceftazidime and meropenem.\n          <\/jats:p>","DOI":"10.1128\/aac.00220-16","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T16:26:28Z","timestamp":1464107188000},"page":"4743-4749","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":146,"title":["<i>In Vitro<\/i>\n            Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)"],"prefix":"10.1128","volume":"60","author":[{"given":"Wright W.","family":"Nichols","sequence":"first","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn L. M.","family":"de Jonge","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Inc., Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp077"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30034-7"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.4.775"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/338782"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00257-10"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70168-3"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01388-12"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.485979"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq306"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03057-14"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02894-14"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-12"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02161-13"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01696-10"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06064-11"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947813Y.0000000145"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02123-13"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05024-14"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.06.008"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.033"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03056-15"},{"key":"e_1_3_3_26_2","volume-title":"Avycaz: ceftazidime-avibactam prescribing information","author":"Forest Pharmaceuticals","year":"2015","unstructured":"Forest Pharmaceuticals. 2015. Avycaz: ceftazidime-avibactam prescribing information. Forest Pharmaceuticals, Inc., Cincinnati, OH."},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkv004","article-title":"Selection and molecular characterization of ceftazidime\/avibactam resistant-mutants in Pseudomonas aeruginosa strains containing derepressed AmpC","volume":"70","author":"Lahiri SD","year":"2015","unstructured":"Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, Nash TJ, Thresher J, Johnstone MR, Hajec L, Livchak S, McLaughlin RE, Alm RA. 2015. Selection and molecular characterization of ceftazidime\/avibactam resistant-mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 70:1650\u20131658.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04146-14"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku551"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04238-14"},{"key":"e_1_3_3_31_2","unstructured":"Bouchillon S Hoban D Hackel M Badal R Morrissey I Nichols WW. 2014. Abstr 24th Eur Congr Clin Microbiol Infect Dis abstr P1782."},{"key":"e_1_3_3_32_2","unstructured":"Biedenbach D de Jonge B Nichols WW Sahm DF. 2015. Abstr 25th Eur Congr Clin Microbiol Infect Dis abstr P1294."},{"key":"e_1_3_3_33_2","unstructured":"Hackel M Stone G de Jonge BLM Sahm DF. 2016. Abstr 26th Eur Congr Clin Microbiol Infect Dis abstr P0297."},{"key":"e_1_3_3_34_2","unstructured":"Sahm D Morrissey I Nichols WW. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother abstr C-768."},{"key":"e_1_3_3_35_2","volume-title":"Performance standards for antimicrobial susceptibility testing, 25th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_36_2","volume-title":"Approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.08.025"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.01.004"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.009142-0"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_3_42_2","unstructured":"AstraZeneca. 2015. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults with nosocomial pneumonia. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01808092. Accessed 11 November 2015."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00220-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00220-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:56:55Z","timestamp":1645477015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00220-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1128\/AAC.00220-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00220-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"2016-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}